Helioverse Innovations today announced its official launch. The company, led by CEO Dr. Taiyo Kuroda, will focus on developing next-generation implantable medical devices that use wireless power transfer as a core enabling technology.

Dr. Kuroda brings the experience as a cardiac surgeon and a track record of research and device development at the Cleveland Clinic. Leveraging this clinical and translational R&D background, Helioverse aims to develop an artificial heart and other implantable systems that are driven by advanced wireless power solutions and designed for long-term, patient-centered use.

Our mission is to transform patient care with advanced bioelectronic solutions that are safe, long-lasting, and minimally invasive. Helioverse aims to reduce the burden of external drivelines and improve quality of life for patients who require long-term cardiac support by integrating compact implantable power systems, magnetic levitation/precision pump designs, and intelligent control algorithms.

Helioverse’s staged R&D program will combine preclinical validation, rigorous engineering, and regulatory planning, pursued in partnership with academic and industry collaborators. The company plans to publish technical updates as milestones are reached and welcomes inquiries from potential collaborators and investors.

“Patient safety, clinical insight, and engineering rigor guide everything we do,” said Dr. Taiyo Kuroda, CEO. “Drawing on years of surgical practice and device development work, we are committed to building a wireless-powered artificial heart and companion implantable technologies that deliver reliable, sustainable support for patients.”

For more information, visit our website or contact our communications team.